Immunization with synthetic mRNA encoding tumor-associated antigens is an emerging
vaccine strategy for the treatment of cancer. In order to prevent mRNA degradation, promote …

To date, many clinical trials have been carried out with neoantigen-specific mRNA vaccines,
and positive results have been achieved. However, further improvements in the efficiency of …

Abstract mRNA-based vaccines have the benefit of triggering robust anti-cancer immunity
without the potential danger of genome integration from DNA vaccines or the limitation of …

Recently, the use of mRNA-based vaccines for cancer immunotherapy has gained growing
attention. Several studies have shown that mRNA delivered in a vectorized format can …

Intracellular delivery of messenger RNA (mRNA)-based cancer vaccine has shown great
potential to elicit antitumor immunity. To achieve robust antitumor efficacy, mRNA encoding …

The targeted delivery of messenger RNA (mRNA) to desired organs remains a great
challenge for in vivo applications of mRNA technology. For mRNA vaccines, the targeted …

Cancer vaccines may be harnessed to incite immunity against poorly immunogenic tumors,
however they have failed in therapeutic settings. Poor antigenicity coupled with systemic …

A novel and improved vaccine delivery system and/or adjuvant is actively sought to enhance
the potency of vaccines. Previously, we reported that strong antitumor immunity could be …

Clinical trials with direct administration of synthetic mRNAs encoding tumor antigens
demonstrated safety and induction of tumor-specific immune responses. Their proper …

For efficient cancer vaccines, the antitumor function largely relies on cytotoxic T cells, whose
activation can be effectively induced via antigen-encoding mRNA, making mRNA-based …